Quest Diagnostics Inc: Form 10-Q for the period ended Mar 31, 2025
Filed with the SEC on Apr 23, 2025 and accepted by EDGAR at Apr 23, 2025, 16:21 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-01-01 to 2025-03-31 | $2.65bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2025-01-01 to 2025-03-31 | $1.79bn | us-gaap:CostOfRevenue |
| Selling, general and administrative | 3 months2025-01-01 to 2025-03-31 | $476.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2025-01-01 to 2025-03-31 | $346.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2025-01-01 to 2025-03-31 | $59.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-01-01 to 2025-03-31 | $220.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-01-01 to 2025-03-31 | $1.94 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-01-01 to 2025-03-31 | $1.97 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-01-01 to 2025-03-31 | 113,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2025-01-01 to 2025-03-31 | $314.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2025-01-01 to 2025-03-31 | $117.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2025-01-01 to 2025-03-31 | $84.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | At period end2025-03-31 | $188.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-03-31 | $2.08bn | us-gaap:AssetsCurrent |
| Total assets | At period end2025-03-31 | $15.80bn | us-gaap:Assets |
| Current liabilities | At period end2025-03-31 | $1.44bn | us-gaap:LiabilitiesCurrent |
| Current portion of debt | At period end2025-03-31 | $1.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2025-03-31 | $6.93bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001022079-25-000120. Last ingested by Listed: Nov 5, 2026, 21:54 ET. Listed shows no prices and gives no investment advice.